Literature DB >> 10588540

An evaluation of the toxicities of 2'-fluorouridine and 2'-fluorocytidine-HCl in F344 rats and woodchucks (Marmota monax).

F C Richardson1, B C Tennant, D J Meyer, K A Richardson, P C Mann, G R McGinty, J L Wolf, P M Zack, R A Bendele.   

Abstract

The toxicities of 2'-fluorouridine (2'-FU) and 2'-fluorocytidine-HCl (2'-FC) were separately evaluated in 2 species, male Fischer 344 (F334) rats and woodchucks. Particular attention was focused on the ability of these nucleosides to induce toxicities similar to those induced by the antiviral drug fialuridine (FIAU). 2'-FU or 2'-FC was administered to F344 male rats by intravenous injection at doses of 5, 50, and 500 mg/kg/day for 90 consecutive days and to male and female woodchucks at doses of 0.75 and 7.5 mg/kg/day for 90 consecutive days. Clinical chemistry, hematology, and urinalysis (woodchuck only) profiles were assessed during and at the termination of the study. At necropsy, organs were weighed and tissues collected for routine histologic analysis. Cytochrome c oxidase activity, citrate synthase activity, and mitochondrial DNA content were measured, and micronucleus formation in the bone marrow (rats only) was evaluated. No adverse clinical effects were observed in either species. Rats treated with high doses of either 2'-FU or 2'-FC had body weights that were 90% of those of controls. 2'-FU and 2'-FC both induced a moderate decrease in the median lymphocyte count, and 2'-FC and 2'-FU induced a mild increase in mean corpuscular hemoglobin and mean corpuscular volume. Both compounds caused slight to moderate, reversible, histologic changes in the spleen and thymus. In the woodchuck, 2'-FC caused a slight increase in mean absolute lymphocytes, and 2'-FC and 2'-FU slightly increased hepatic periportal vacuolation and/or mononuclear cell infiltration. In summary, neither compound showed evidence of the toxicity induced by fialuridine in either species. Although compound effects were observed, none of these effects were considered to be adverse, and the no-observed adverse effect level was determined to be 500 mg/kg/day for both compounds in the male F344 rat and 7.5 mg/kg/day in the woodchuck.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588540     DOI: 10.1177/019262339902700601

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  15 in total

Review 1.  Preclinical and clinical development of siRNA-based therapeutics.

Authors:  Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

2.  Evaluation of mitochondrial toxicity in Marmota himalayana treated with metacavir, a novel 2',3'-dideoxyguanosine prodrug for treatment of hepatitis B Virus.

Authors:  Pinghu Zhang; Luyong Zhang; Zhenzhou Jiang; Yating Xiong; Hongkui Chen; Yuanqing Tao; Maozhi Hu; Zhan Li
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  Nucleic acid aptamers for target validation and therapeutic applications.

Authors:  P Shannon Pendergrast; H Nicholas Marsh; Dilara Grate; Judith M Healy; Martin Stanton
Journal:  J Biomol Tech       Date:  2005-09

Review 4.  Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.

Authors:  Fang Liu; Chunfang Wang; Yuantao Gao; Xiao Li; Feng Tian; Yongtao Zhang; Mingyang Fu; Pengfei Li; Yali Wang; Fei Wang
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

5.  Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus.

Authors:  Stephen R Welch; Florine E M Scholte; Mike Flint; Payel Chatterjee; Stuart T Nichol; Éric Bergeron; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2017-10-09       Impact factor: 5.970

6.  Safety evaluation of 2'-deoxy-2'-fluoro nucleotides in GalNAc-siRNA conjugates.

Authors:  Maja M Janas; Ivan Zlatev; Ju Liu; Yongfeng Jiang; Scott A Barros; Jessica E Sutherland; Wendell P Davis; Jingxuan Liu; Christopher R Brown; Xiumin Liu; Mark K Schlegel; Lauren Blair; Xuemei Zhang; Biplab Das; Chris Tran; Krishna Aluri; Jing Li; Saket Agarwal; Ramesh Indrakanti; Klaus Charisse; Jayaprakash Nair; Shigeo Matsuda; Kallanthottathil G Rajeev; Tracy Zimmermann; Laura Sepp-Lorenzino; Yuanxin Xu; Akin Akinc; Kevin Fitzgerald; Akshay K Vaishnaw; Peter F Smith; Muthiah Manoharan; Vasant Jadhav; Jing-Tao Wu; Martin A Maier
Journal:  Nucleic Acids Res       Date:  2019-04-23       Impact factor: 16.971

7.  In vivo assessment of mitochondrial toxicity of metacavir in Rhesus monkeys after three months of intravenous administration.

Authors:  Wen Zeng; An-chun Cheng; Zheng-li Chen; Qi-hui Luo; Yu-bo Sun; Zhan Li; Feng-jun Bi
Journal:  Acta Pharmacol Sin       Date:  2009-11-16       Impact factor: 6.150

8.  2'-fluoro-2'-deoxycytidine inhibits Borna disease virus replication and spread.

Authors:  Jeffrey J Bajramovic; Romain Volmer; Sylvie Syan; Sylvie Pochet; Daniel Gonzalez-Dunia
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

9.  In vitro selection of RNA aptamers against a conserved region of the Plasmodium falciparum erythrocyte membrane protein 1.

Authors:  Anders Barfod; Tina Persson; Johan Lindh
Journal:  Parasitol Res       Date:  2009-08-20       Impact factor: 2.289

10.  Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2'-deoxy-2'-fluorocytidine.

Authors:  Lieven J Stuyver; Tamara R McBrayer; Tony Whitaker; Phillip M Tharnish; Mangala Ramesh; Stefania Lostia; Leanne Cartee; Junxing Shi; Ann Hobbs; Raymond F Schinazi; Kyoichi A Watanabe; Michael J Otto
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.